article thumbnail

Touchdown: Novartis Named First-ever Corporate Pharmaceutical Partner of the NFL

The Dermatology Digest

Novartis is the official first-in-category corporate pharmaceutical partner of the National Football League (NFL). “We’re thrilled to welcome Novartis as our first-ever corporate partner across the pharmaceutical category,” says Senior Vice President, Sponsorship at the NFL Tracie Rodburg.

article thumbnail

Medical Grade Skincare vs. Over-the-Counter Products: What’s the Difference?

Kim Gallo Esthetics

Also known as pharmaceutical-grade , medical-grade skincare is exactly what it sounds like - products that are both developed and tested by medical professionals. FDA regulated Medical-grade skincare products are regulated by the FDA to ensure they meet safety and quality standards. What is medical-grade skincare?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO

The Dermatology Digest

Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) ” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed.

article thumbnail

A Glimpse Inside the Lichen Planus Pipeline

The Dermatology Digest

LP-310, developed by Lipella Pharmaceuticals for the treatment of oral lichen planus (OLP), is currently in Phase 2 clinical trials. Lipella has received an Investigational New Drug (IND) approval for a Phase 2a multicenter dose-escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP.

article thumbnail

Exploring the Role of Topical ET-02 in Androgenic Alopecia

The Dermatology Digest

Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated. Eirion plans to begin a Phase 2 clinical trial (N150) in 2025 with a 6-month treatment period with the goal of confirming ET-02’s safety and efficacy. A final assessment of the subjects was made one week after the treatments ended.

Safety 36
article thumbnail

The Evolution of Dermal Fillers in Non-Surgical Aesthetics

Lipgloss and Aftershave

The availability of hyaluronidase, an enzyme used to dissolve hyaluronic acid fillers, has provided a safety net for both practitioners and patients. He has authored a textbook on Aesthetic Medicine, published over 35 scientific papers, and serves as a Global Advisor for major pharmaceutical companies.

Facials 52
article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

“It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.”